Sartorius Stedim Biotech (DIM) Q4 2025 earnings summary

Executive summary

• Achieved and exceeded FY 2025 guidance with strong revenue and margin growth, led by recurring consumables and improved operational performance across both divisions.

• Margin expansion was driven by scale, favorable product mix, and occurred despite FX and US tariff headwinds.

• Operational improvements enabled deleveraging and reinforced a strong balance sheet.

• Strategic investments in innovation, sustainability, and global capacity expansion position the company for sustainable, innovation-led growth.

• Confident outlook for 2026, expecting continued growth and profitability.

Financial highlights

• Sales revenue increased by 9.6% in constant currencies (7.6% in some reports), reaching over €3.5 billion, with Bioprocess Solutions up 9.5% and Lab Products & Services up 0.2%.

• Underlying EBITDA rose 17.3% to €1.052 billion, margin expanding to 30.8%–29.7%.

• Underlying net profit grew 18%–26.7%, reported net profit up 51.7%–84%, and underlying EPS increased to €4.78.

• Operating cash flow was €837 million; free cash flow ranged from €295 million to €390 million.

• Equity ratio improved to 39.8%–51.7%; leverage ratio (net debt/EBITDA) improved to 2.38–3.55x.

Outlook and guidance

• 2026 group sales growth expected at 5%–10% in constant currencies, with EBITDA margin slightly above 30%.

• BPS sales growth forecast at 6%–10%, with margin slightly above 32%; LPS sales growth at 2%–6%, margin slightly below 21%.

• CapEx ratio to remain around 12.5%–13.3%; leverage ratio to decrease to slightly above 2–3x.

• Guidance reflects ongoing macroeconomic, industry-specific, and geopolitical volatility, with a broad range to reflect uncertainty.

• Guidance excludes potential additional US tariffs.